The global flexible manufacturing systems for pharmaceutical industry market revenue was around US$ 2.2 billion in 2023 and is estimated to reach US$ 3.5 billion by 2032, growing at a compound annual growth rate (CAGR) of 5.3% during the forecast period from 2024 to 2032.
Flexible manufacturing systems for pharmaceuticals include all the systems that are meant to fast adapt to the changes in the market and industry needs with regards to the pharmaceutical industry. These systems allow pharmaceutical producers to create effective usage of their plants, facilities, and other capacities to stay beneficial and competitive.
Market Driving Factors
The increasing global population, mainly the old-age population has enormously raised the number of patients suffering from rare and common diseases. This has increased the demand for generic and specialized drugs and different pharmaceuticals. Additionally, the large investment for healthcare facilities in developed nations drives the growth in the pharmaceutical industry. Therefore, such elements are estimated to drive market growth. For instance, according to the World Health Organization, the number of individuals aged 60 years and older was 1 billion in 2019 and is estimated to increase by 1.4 billion by 2030 and 2.1 billion by 2050. As a result, this surge in the number of patients suffering from different chronic disorders.
The development of creative drugs such as biologics and personalized medicine is predicted to drive the market. This is because it needs flexible and adaptable manufacturing procedures. Thus, flexible manufacturing systems (FMS) can enable efficient production of these complicated formulations.
The need for highly professional for managing and developing flexible manufacturing systems for pharmaceuticals is a major constraint in the market.
Regional Analysis
In 2023, North America dominated the market in terms of growth rate and is estimated to maintain its dominance during the forecast period. This can be mainly attributed to the existence of established pharmaceutical firms, strong healthcare infrastructure, and profitable regulatory circumstances.
Asia Pacific region dominates the market in terms of shares. This is primarily owing to the expanding pharmaceutical markets in nations such as India and China, along with surging investments in healthcare infrastructure. In addition, they provide untapped possibilities for key players, driven by enhancing healthcare systems and surging access to healthcare services.
Segmentation Insights
Product Type Insight
The modular manufacturing segment dominates the market in terms of the largest shares. This is mainly due to its several benefits and features that lower the overall price of production and raise the reliability of the process.
Technology Insight
The software segment is estimated to dominate the market in terms of growth rate. This is owing to the increase in the geriatric population and the surge in investment in the healthcare industry.
Prominent Companies
Segmentation Outline
The global flexible manufacturing systems for pharmaceutical industry market segmentation focuses on Product Type, Technology, End User Industry, and Region.
By Product Type
By Technology
By End User Industry
By Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL FLEXIBLE MANUFACTURING SYSTEMS FOR PHARMACEUTICAL INDUSTRY MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY: FLEXIBLE MANUFACTURING SYSTEMS FOR PHARMACEUTICAL INDUSTRY MARKET
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
3.5 ANALYST TOOLS AND MODELS
4 GLOBAL FLEXIBLE MANUFACTURING SYSTEMS FOR PHARMACEUTICAL INDUSTRY MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS AND TRENDS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS
4.5 MARKET GROWTH AND OUTLOOK
4.5.1 PRICE TREND ANALYSIS
4.5.2 OPPORTUNITY SHARE
5 GLOBAL FLEXIBLE MANUFACTURING SYSTEMS FOR PHARMACEUTICAL INDUSTRY MARKET, BY PRODUCT TYPE
5.1 OVERVIEW
5.2 MODULAR MANUFACTURING
5.3 DATA-DRIVEN MANUFACTURING
5.4 SINGLE-USE MANUFACTURING
5.5 CONTINUOUS MANUFACTURING
6 GLOBAL FLEXIBLE MANUFACTURING SYSTEMS FOR PHARMACEUTICAL INDUSTRY MARKET, BY TECHNOLOGY
6.1 OVERVIEW
6.2 HARDWARE
6.3 SOFTWARE
7 GLOBAL FLEXIBLE MANUFACTURING SYSTEMS FOR PHARMACEUTICAL INDUSTRY MARKET, BY END USER INDUSTRY
7.1 OVERVIEW
7.2 LARGE PHARMACEUTICAL MANUFACTURERS
7.2.1 METHOD
7.2.1.1 MACHINE FLEXIBILITY
7.2.1.2 VOLUME FLEXIBILITY
7.3 MEDIUM AND SMALL PHARMACEUTICAL MANUFACTURERS
8 GLOBAL FLEXIBLE MANUFACTURING SYSTEMS FOR PHARMACEUTICAL INDUSTRY MARKET, BY GEOGRAPHY
8.1 OVERVIEW
8.2 NORTH AMERICA
8.2.1 NORTH AMERICA MARKET SNAPSHOT
8.2.2 U.S.
8.2.3 CANADA
8.2.4 MEXICO
8.3 EUROPE
8.3.1 EUROPE MARKET SNAPSHOT
8.3.2 WESTERN EUROPE
8.3.2.1 THE UK
8.3.2.2 GERMANY
8.3.2.3 FRANCE
8.3.2.4 ITALY
8.3.2.5 SPAIN
8.3.2.6 REST OF WESTERN EUROPE
8.3.3 EASTERN EUROPE
8.3.3.1 POLAND
8.3.3.2 RUSSIA
8.3.3.3 REST OF EASTERN EUROPE
8.4 ASIA PACIFIC
8.4.1 ASIA PACIFIC MARKET SNAPSHOT
8.4.2 CHINA
8.4.3 JAPAN
8.4.4 INDIA
8.4.5 AUSTRALIA & NEW ZEALAND
8.4.6 ASEAN
8.4.7 REST OF ASIA PACIFIC
8.5 MIDDLE EAST & AFRICA
8.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
8.5.2 UAE
8.5.3 SAUDI ARABIA
8.5.4 SOUTH AFRICA
8.5.5 REST OF MEA
8.6 SOUTH AMERICA
8.6.1 SOUTH AMERICA MARKET SNAPSHOT
8.6.2 BRAZIL
8.6.3 ARGENTINA
8.6.4 REST OF SOUTH AMERICA
9 GLOBAL FLEXIBLE MANUFACTURING SYSTEMS FOR PHARMACEUTICAL INDUSTRY MARKET COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPANY MARKET RANKING
9.3 KEY DEVELOPMENT STRATEGIES
9.4 COMPETITIVE DASHBOARD
9.5 PRODUCT MAPPING
9.6 TOP PLAYER POSITIONING, 2022
9.7 COMPETITIVE HEATMAP
9.8 TOP WINNING STRATEGIES
10 COMPANY PROFILES
10.1 KEYPLANTS AB
10.1.1 OVERVIEW
10.1.2 FINANCIAL PERFORMANCE
10.1.3 PRODUCT OUTLOOK
10.1.4 KEY DEVELOPMENTS
10.1.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.2 MODWAVE LLC
10.2.1 OVERVIEW
10.2.2 FINANCIAL PERFORMANCE
10.2.3 PRODUCT OUTLOOK
10.2.4 KEY DEVELOPMENTS
10.2.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.3 EXYTE GMBH
10.3.1 OVERVIEW
10.3.2 FINANCIAL PERFORMANCE
10.3.3 PRODUCT OUTLOOK
10.3.4 KEY DEVELOPMENTS
10.3.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.4 NNE
10.4.1 OVERVIEW
10.4.2 FINANCIAL PERFORMANCE
10.4.3 PRODUCT OUTLOOK
10.4.4 KEY DEVELOPMENTS
10.4.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.5 PR PHARMA ENGINEERS PVT LTD
10.5.1 OVERVIEW
10.5.2 FINANCIAL PERFORMANCE
10.5.3 PRODUCT OUTLOOK
10.5.4 KEY DEVELOPMENTS
10.5.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.6 IPM TECHNOLOGIES
10.6.1 OVERVIEW
10.6.2 FINANCIAL PERFORMANCE
10.6.3 PRODUCT OUTLOOK
10.6.4 KEY DEVELOPMENTS
10.6.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.7 BIOLOGICS MODULAR LLC
10.7.1 OVERVIEW
10.7.2 FINANCIAL PERFORMANCE
10.7.3 PRODUCT OUTLOOK
10.7.4 KEY DEVELOPMENTS
10.7.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.8 PHARMADULE MORIMATSU AB
10.8.1 OVERVIEW
10.8.2 FINANCIAL PERFORMANCE
10.8.3 PRODUCT OUTLOOK
10.8.4 KEY DEVELOPMENTS
10.8.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.9 CYTIVA
10.9.1 OVERVIEW
10.9.2 FINANCIAL PERFORMANCE
10.9.3 PRODUCT OUTLOOK
10.9.4 KEY DEVELOPMENTS
10.9.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.10 NICOMAC SRL
10.10.1 OVERVIEW
10.10.2 FINANCIAL PERFORMANCE
10.10.3 PRODUCT OUTLOOK
10.10.4 KEY DEVELOPMENTS
10.10.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.11 MODULECO LTD
10.11.1 OVERVIEW
10.11.2 FINANCIAL PERFORMANCE
10.11.3 PRODUCT OUTLOOK
10.11.4 KEY DEVELOPMENTS
10.11.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.12 ANGSTROM TECHNOLOGY
10.12.1 OVERVIEW
10.12.2 FINANCIAL PERFORMANCE
10.12.3 PRODUCT OUTLOOK
10.12.4 KEY DEVELOPMENTS
10.12.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.13 CHEMPHARM
10.13.1 OVERVIEW
10.13.2 FINANCIAL PERFORMANCE
10.13.3 PRODUCT OUTLOOK
10.13.4 KEY DEVELOPMENTS
10.13.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.14 G-CON MANUFACTURING
10.14.1 OVERVIEW
10.14.2 FINANCIAL PERFORMANCE
10.14.3 PRODUCT OUTLOOK
10.14.4 KEY DEVELOPMENTS
10.14.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.15 UNIVERCELLS TECHNOLOGIES
10.15.1 OVERVIEW
10.15.2 FINANCIAL PERFORMANCE
10.15.3 PRODUCT OUTLOOK
10.15.4 KEY DEVELOPMENTS
10.15.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.16 ESC (ENVIRONMENTAL SYSTEMS CORPORATION)
10.16.1 OVERVIEW
10.16.2 FINANCIAL PERFORMANCE
10.16.3 PRODUCT OUTLOOK
10.16.4 KEY DEVELOPMENTS
10.16.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.17 GERMFREE LABORATORIES INC.
10.17.1 OVERVIEW
10.17.2 FINANCIAL PERFORMANCE
10.17.3 PRODUCT OUTLOOK
10.17.4 KEY DEVELOPMENTS
10.17.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved